abstract |
Use of an LFA-1 antagonist and a TNF-alpha antagonist in the preparation of a medicament for treating rheumatoid arthritis, wherein the LFA-1 antagonist is an anti-CD11a antibody, and the TNF-alpha antagonist is an immunoadhesin comprising at least one TNF-alpha binding portion of the p75 TNF-alpha receptor. |